Ben Powell
Opna Bio (United States) · 36 works · 4,971 citations · h-index 15
Top works
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- Structural Basis for the Activity of Drugs that Inhibit Phosphodiesterases
- RAF inhibitors that evade paradoxical MAPK pathway activation
- Composition and Assembly of the Yeast Vacuolar H+-ATPase Complex
- Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 “Gatekeeper” F691L Mutation with PLX3397
- Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor
- Molecular Characterization of the Yeast Vacuolar H+-ATPase Proton Pore
- The crystal structures of human steroidogenic factor-1 and liver receptor homologue-1
- Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase
- BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
- Identification of Lipid-Accessible Sites on the Nephrops 16-kDa Proteolipid Incorporated into a Hybrid Vacuolar H+-ATPase: Site-Directed Labeling with N-(1-Pyrenyl)cyclohexylcarbodiimide and Fluorescence Quenching Analysis
- Helical Interactions and Membrane Disposition of the 16-kDa Proteolipid Subunit of the Vacuolar H+-ATPase Analyzed by Cysteine Replacement Mutagenesis
- BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression
- Inhibition of Bromodomain and Extra Terminal (BET) Domain Activity Modulates the IL-23R/IL-17 Axis and Suppresses Acute Graft-Versus-Host Disease
- Final Results of a Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- Co-Targeting BET Bromodomain Proteins and Aberrant Signaling in AML
- Efficacy and Mechanism of Action of the Novel Bromodomain Inhibitor, PLX51107, in B Cell Malignancies
- Abstract A229: BRAF inhibitors upregulate EGFR ligands: A molecular link to RAF inhibitor-induced cutaneous squamous cell carcinomas.
- Catalytic Domain Of Human Phosphodiesterase 4B In Complex With (R)-Mesopram